Stock Market News
4D Pharma cancer treatment shown to stimulate immune system response
Pharmaceutical company 4D Pharma reported on Wednesday that its lead oncology candidate has demonstrated immune-stimulatory characteristics in pre-clinical models.
The MRx0518 is a strain of live bacteria extracted and purified from healthy human faecal samples developed to stimulate pathways that are associated with the body's response to cancer and has seen a successful development programme at 4D Pharma's GMP production plant.
Duncan Peyton, chief executive of 4D Pharma, said: "This is a key step in the development of a true microbiome derived pharmaceutical product for the treatment of cancer. Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients."
The company said that plans are at an advanced stage to open UK and US based clinical studies in the near future.
Data concerning the MRx0518 bacteria was presented at the Microbiome Research and Development and Business Collaboration Forum in Rotterdam on Wednesday by Peyton.
As of 1106 GMT, 4D Pharma's shares were up 3.08% at 134.00p.
The MRx0518 is a strain of live bacteria extracted and purified from healthy human faecal samples developed to stimulate pathways that are associated with the body's response to cancer and has seen a successful development programme at 4D Pharma's GMP production plant.
Duncan Peyton, chief executive of 4D Pharma, said: "This is a key step in the development of a true microbiome derived pharmaceutical product for the treatment of cancer. Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients."
The company said that plans are at an advanced stage to open UK and US based clinical studies in the near future.
Data concerning the MRx0518 bacteria was presented at the Microbiome Research and Development and Business Collaboration Forum in Rotterdam on Wednesday by Peyton.
As of 1106 GMT, 4D Pharma's shares were up 3.08% at 134.00p.
Related share prices |
---|
4D Pharma (DDDD) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price